Market Closed - Nasdaq 04:00:00 2024-09-10 pm EDT 5-day change 1st Jan Change
21.66 USD -0.73% Intraday chart for 10x Genomics, Inc. -5.95% -61.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : 10x Genomics, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:45 AM
10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments CI
Leerink Partners Initiates 10x Genomics at Outperform MT
UBS Adjusts Price Target on 10x Genomics to $25 From $30, Maintains Neutral Rating MT
Tech, Yen, and Jobs: Wall Street's triple play Our Logo
Analyst recommendations: Epam Systems, Five9, T-Mobile, Lyft, Under Armour... Our Logo
Earnings Flash (TXG) 10X GENOMICS Posts Q2 Revenue $153.1M MT
Earnings Flash (TXG) 10X GENOMICS Posts Q2 Loss $-0.32 MT
Transcript : 10x Genomics, Inc., Q2 2024 Earnings Call, Aug 08, 2024
10x Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
10X Genomics, Inc. Appoints Mennah Moustafahas as Chief Commercial Officer CI
10X Genomics, Inc. Announces CFO Changes CI
10X Genomics, Inc. Revises Earnings Guidance for Full Year 2024 CI
10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases CI
Canaccord Genuity Adjusts Price Target on 10x Genomics to $32 From $50, Maintains Buy Rating MT
Tech's Judgment Day Our Logo
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap... Our Logo
10x Genomics Shares Rise Following Jefferies Upgrade MT
Biden bows out, Wall Street bounces up Our Logo
Top Premarket Gainers MT
Jefferies Upgrades 10x Genomics to Buy From Hold, Price Target is $24 MT
Analyst recommendations: Crowdstrike, Estee Lauder, Lyft, Nvidia, Rentokil... Our Logo
10x Genomics Shares Fall After JPMorgan Downgrade MT
BofA Securities Adjusts Price Target on 10x Genomics to $25 From $36 MT
JPMorgan Downgrades 10x Genomics to Neutral From Overweight, Adjusts Price Target to $20 From $40 MT
Chart 10x Genomics, Inc.
More charts
Logo 10x Genomics, Inc.
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Employees
1,259
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
21.66USD
Average target price
27.29USD
Spread / Average Target
+25.97%
Consensus
  1. Stock Market
  2. Equities
  3. TXG Stock
  4. News 10x Genomics, Inc.
  5. Earnings Flash (TXG) 10X GENOMICS Posts Q2 Revenue $153.1M
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW